ADMA Biologics, Inc. (ADMA): Operating Income
$191.44M
Year ended 2025-12-31
$224.48M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $191.44M | +37.7% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $138.98M | +542.5% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $21.63M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$39.37M | n/m | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | -$58.37M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$64.91M | n/m | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | -$41.42M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$60.29M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$39.31M | n/m | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | -$17.33M | n/m | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | -$15.51M | n/m | 2017-02-24, From 2015-01-01 |
| 2014-12-31 | -$16.02M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | -$15.04M | n/m | 2015-03-09, From 2013-01-01 |
| 2012-12-31 | -$7.91M | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$4.62M | n/a | 2013-03-06, From 2011-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $191.44M | +37.7% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | -$70.97M | n/m |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$45.35M | n/m |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $161.29M | +145.3% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$136.26M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $55.17M | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $340.99M | n/m |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$57.12M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $11.04M | +144.4% |
Compare ADMA, TARS, IMCR, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗